Name: Late-stage microscopic assay to identify inhibitors of NADPH oxidase 1 (NOX1): Inhibition of invadopodia formation ..more
Related BioAssays
Related BioAssays
Target
| Sequence: NADPH oxidase 1 [Homo sapiens] Protein Family: NOX_Duox_like_FAD_NADP Gene:NOX1 Related Protein 3D Structures |
BioActive Compound: 1
Depositor Specified Assays
Show more |
| AID | Name | Type | Probe | Comment |
|---|---|---|---|---|
| 1792 | Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of NADPH oxidase 1 (Nox1): Maybridge Library | screening | Primary Screen (NOX1 inhibitors) | |
| 1796 | Summary of probe development efforts to identify inhibitors of NADPH oxidase 1 (Nox1) | summary | 2 | Summary AID (NOX1 inhibitors) |
| 1823 | Luminescence-based counterscreen for inhibitors of NADPH oxidase 1 (Nox1): biochemical high throughput screening assay to identify inhibitors of luminol (Maybridge Library) | screening | Counterscreen (luminal) | |
| 2532 | Late stage results from the probe development effort to identify inhibitors of NOX1: HEK/293 IC50 | confirmatory | Dose response (NOX1 inhibitors, HEK/293 cells) | |
| 2538 | Luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1) | confirmatory | Dose response screen (NOX1 inhibitors) | |
| 2539 | Late stage results from the probe development effort to identify inhibitors of (NADPH oxidase 1) NOX1: Family selectivity | screening | Counterscreen (NOX2, NOX3, NOX4 inhibitors) | |
| 2541 | Luminescence-based cell-based assay to identify inhibitors of NADPH oxidase 1 (NOX1) | screening | Confirmation screen (NOX1 inhibitors) | |
| 2545 | Late stage results from the probe development effort to identify inhibitors of (NADPH oxidase 1) NOX1: HEK/293 percent inhibition | screening | Confirmation screen (NOX1 inhibitors, HEK/293 cells) | |
| 2556 | Late stage results from the probe development effort to identify inhibitors of (NADPH oxidase 1) NOX1: Xanthine Oxidase | confirmatory | Counterscreen (Xanthine oxidase inhibitors) | |
| 2664 | Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Synthesized analogs | confirmatory | Primary screen (NOX1 inhibitors, synthesized analogs) | |
| 2752 | Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Synthesized analogs 2 | confirmatory | Primary screen (NOX1 inhibitors, synthesized analogs set 2) | |
| 2773 | Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Synthesized analogs 3 | confirmatory | Primary screen (NOX1 inhibitors, synthesized analogs set 3) | |
| 2808 | Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Purchased analogs | confirmatory | Primary screen (NOX1 inhibitors, purchased analogs) | |
| 2819 | Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Purchased analogs 2 | confirmatory | Primary screen (NOX1 inhibitors, purchased analogs set 2) | |
| 434974 | Late-stage radioligand binding assay to identify inhibitors of NADPH oxidase 1 (NOX1): PDSP screen | screening | Psychoactive Drug Screening Program primary screen (NOX1 inhibitors) | |
| 434953 | Late-stage radioligand binding dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): PDSP screen Ki | screening | Psychoactive Drug Screening Program secondary screen (NOX1 inhibitors) | |
| 463255 | Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Cytotoxicity assay 2 | confirmatory | ||
| 488778 | Late-stage microscopic assay to identify inhibitors of NADPH oxidase 1 (NOX1): Inhibition of extracellular matrix degradation | other | ||
| 504381 | Late-stage radioligand binding assay to identify inhibitors of NADPH oxidase 1 (NOX1): PDSP screen Set 2 | other | ||
| 504410 | Late-stage radioligand binding dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): PDSP screen Ki Set 2 | confirmatory |
Description:
Data Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Center Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Gary Bokoch, TSRI
Network: Molecular Libraries Probe Production Center Network (MLPCN)
Grant Proposal Number: 1 R03 MH083264-01A1
Grant Proposal PI: Gary Bokoch, TSRI
External Assay ID: NOX1_INH_FLUOR_MIC
Name: Late-stage microscopic assay to identify inhibitors of NADPH oxidase 1 (NOX1): Inhibition of invadopodia formation
Description:
Host defense mechanisms are diverse and include receptor-initiated signaling pathways, antibody and cytokine production, and the generation of reactive oxygen species (ROS) such as hydroxyl radical and hypochlorus acid to kill microorganisms (1). In activated phagocytic cells, the membrane integrated protein gp91phox serves as the catalytic cytochrome b subunit of the respiratory burst oxidase used to generate superoxide in an NADPH-dependent manner for host defense (2). Generation of ROS has also been identified in non-phagocytic cells (3). One important enzyme involved in ROS production in non-leukocyte tissues is NADPH oxidase 1 (NOX1), a homolog of gp91phox. NOX1 is highly expressed in colon epithelial cells where it can generate ROS to interact with normal and pathogenic bacteria (3-5). However, excess ROS production is associated with damage to the intestinal mucosa, particularly in mucosal lesions of inflammatory bowel disease (IBD) (4). Studies showing that NOX1 levels are increased in human prostate cancer (6) and that cells overexpressing NOX1 have a transformed appearance, exhibit anchorage-independent growth, and induce vascularized tumor formation in athymic mice (3, 7), suggest that NOX1 may also play a role in angiogenesis, cell growth, and tumor pathogenesis (8, 9). The identification of inhibitors of NOX1 may lead to potential candidates for excess cell proliferation, cancer, and IBD.
References:
1. Takeya, R. and Sumimoto, H., Molecular mechanism for activation of superoxide-producing NADPH oxidases. Mol Cells, 2003. 16(3): p. 271-7.
2. Cheng, G., Cao, Z., Xu, X., van Meir, E.G., and Lambeth, J.D., Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene, 2001. 269(1-2): p. 131-40.
3. Suh, Y.A., Arnold, R.S., Lassegue, B., Shi, J., Xu, X., Sorescu, D., Chung, A.B., Griendling, K.K., and Lambeth, J.D., Cell transformation by the superoxide-generating oxidase Mox1. Nature, 1999. 401(6748): p. 79-82.
4. Szanto, I., Rubbia-Brandt, L., Kiss, P., Steger, K., Banfi, B., Kovari, E., Herrmann, F., Hadengue, A., and Krause, K.H., Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. J Pathol, 2005. 207(2): p. 164-76.
5. Rokutan, K., Kawahara, T., Kuwano, Y., Tominaga, K., Nishida, K., and Teshima-Kondo, S., Nox enzymes and oxidative stress in the immunopathology of the gastrointestinal tract. Semin Immunopathol, 2008. 30(3): p. 315-27.
6. Lim, S.D., Sun, C., Lambeth, J.D., Marshall, F., Amin, M., Chung, L., Petros, J.A., and Arnold, R.S., Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate, 2005. 62(2): p. 200-7.
7. Arnold, R.S., Shi, J., Murad, E., Whalen, A.M., Sun, C.Q., Polavarapu, R., Parthasarathy, S., Petros, J.A., and Lambeth, J.D., Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci U S A, 2001. 98(10): p. 5550-5.
8. Ushio-Fukai, M. and Nakamura, Y., Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett, 2008. 266(1): p. 37-52.
9. Kobayashi, S., Nojima, Y., Shibuya, M., and Maru, Y., Nox1 regulates apoptosis and potentially stimulates branching morphogenesis in sinusoidal endothelial cells. Exp Cell Res, 2004. 300(2): p. 455-62.
Keywords:
NOX1, NADPH oxidase 1, cancer, inflammation, inhibitor, inhibition, late stage, dose response, invadopodia, DLD1 cells, actin, phalloidin, coractin, epifluorescence microscopy, Scripps, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Center Network, MLPCN.
Center Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Gary Bokoch, TSRI
Network: Molecular Libraries Probe Production Center Network (MLPCN)
Grant Proposal Number: 1 R03 MH083264-01A1
Grant Proposal PI: Gary Bokoch, TSRI
External Assay ID: NOX1_INH_FLUOR_MIC
Name: Late-stage microscopic assay to identify inhibitors of NADPH oxidase 1 (NOX1): Inhibition of invadopodia formation
Description:
Host defense mechanisms are diverse and include receptor-initiated signaling pathways, antibody and cytokine production, and the generation of reactive oxygen species (ROS) such as hydroxyl radical and hypochlorus acid to kill microorganisms (1). In activated phagocytic cells, the membrane integrated protein gp91phox serves as the catalytic cytochrome b subunit of the respiratory burst oxidase used to generate superoxide in an NADPH-dependent manner for host defense (2). Generation of ROS has also been identified in non-phagocytic cells (3). One important enzyme involved in ROS production in non-leukocyte tissues is NADPH oxidase 1 (NOX1), a homolog of gp91phox. NOX1 is highly expressed in colon epithelial cells where it can generate ROS to interact with normal and pathogenic bacteria (3-5). However, excess ROS production is associated with damage to the intestinal mucosa, particularly in mucosal lesions of inflammatory bowel disease (IBD) (4). Studies showing that NOX1 levels are increased in human prostate cancer (6) and that cells overexpressing NOX1 have a transformed appearance, exhibit anchorage-independent growth, and induce vascularized tumor formation in athymic mice (3, 7), suggest that NOX1 may also play a role in angiogenesis, cell growth, and tumor pathogenesis (8, 9). The identification of inhibitors of NOX1 may lead to potential candidates for excess cell proliferation, cancer, and IBD.
References:
1. Takeya, R. and Sumimoto, H., Molecular mechanism for activation of superoxide-producing NADPH oxidases. Mol Cells, 2003. 16(3): p. 271-7.
2. Cheng, G., Cao, Z., Xu, X., van Meir, E.G., and Lambeth, J.D., Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene, 2001. 269(1-2): p. 131-40.
3. Suh, Y.A., Arnold, R.S., Lassegue, B., Shi, J., Xu, X., Sorescu, D., Chung, A.B., Griendling, K.K., and Lambeth, J.D., Cell transformation by the superoxide-generating oxidase Mox1. Nature, 1999. 401(6748): p. 79-82.
4. Szanto, I., Rubbia-Brandt, L., Kiss, P., Steger, K., Banfi, B., Kovari, E., Herrmann, F., Hadengue, A., and Krause, K.H., Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. J Pathol, 2005. 207(2): p. 164-76.
5. Rokutan, K., Kawahara, T., Kuwano, Y., Tominaga, K., Nishida, K., and Teshima-Kondo, S., Nox enzymes and oxidative stress in the immunopathology of the gastrointestinal tract. Semin Immunopathol, 2008. 30(3): p. 315-27.
6. Lim, S.D., Sun, C., Lambeth, J.D., Marshall, F., Amin, M., Chung, L., Petros, J.A., and Arnold, R.S., Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate, 2005. 62(2): p. 200-7.
7. Arnold, R.S., Shi, J., Murad, E., Whalen, A.M., Sun, C.Q., Polavarapu, R., Parthasarathy, S., Petros, J.A., and Lambeth, J.D., Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci U S A, 2001. 98(10): p. 5550-5.
8. Ushio-Fukai, M. and Nakamura, Y., Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett, 2008. 266(1): p. 37-52.
9. Kobayashi, S., Nojima, Y., Shibuya, M., and Maru, Y., Nox1 regulates apoptosis and potentially stimulates branching morphogenesis in sinusoidal endothelial cells. Exp Cell Res, 2004. 300(2): p. 455-62.
Keywords:
NOX1, NADPH oxidase 1, cancer, inflammation, inhibitor, inhibition, late stage, dose response, invadopodia, DLD1 cells, actin, phalloidin, coractin, epifluorescence microscopy, Scripps, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Center Network, MLPCN.
Panel Information
Protocol
Assay Overview:
The purpose of this assay is to determine whether a compound that inhibits NOX1 can block invadopodia formation in DLD1 human colon cancer cells. Invadopodia are dynamic phosphotyrosine-rich structures with an actin core and abundant actin regulatory proteins (e.g. cortactin) capable of proteolytically degrading the ECM. They appear as actin protrusions of the ventral plasma membrane and their formation in human cancer cells correlates with their invasiveness both in vitro and in vivo. Recent evidence indicates that NOX-mediated ROS generation is required for invadopodia formation in different cancer cells. In this assay, cells are transfected with tyrosine kinase c-Src, which is required for the formation of functional invadopodia. Cells are then treated with test or control compounds, then stained with invadopodia markers phalloidin or cortactin, and then prepared for confocal and epifluorescence microscopy. As designed, a compound that inhibits NOX1 will inhibit invadopodia formation and result in fewer phalloidin- and contactin-positive structures.
Protocol Summary:
DLD1 cells were transfected with empty vector or with constitutive active Src (SrcYF) to trigger the formation of invadopodia and then treated for 1hr with compound SID 57287864, or DMSO or DPI which were used as negative or positive controls respectively. 24 hrs after transfection, DLD1 cells plated on glass or FITC-labeled gelatin-coated coverslips were fixed in 4% paraformaldehyde (PFA) at room temperature for 10 minutes. Successively, cells were permeabilized in 0.5% Triton for 10 minutes and blocked in 2%BSA in PBS for 45 minutes at room temperature. Cells were then immunolabeled as indicated in the figure legends with appropriate primary and Alexa-Fluor 568-conjugated secondary antibodies. F-actin was detected by using Alexa-Fluor 568-conjugated phalloidin. Cells were mounted on slides with Mowiol mounting medium (Calbiochem) according to the manufacturer's instructions. Epifluorescence images of fixed cells were acquired on an inverted microscope (Eclipse TE 2000-U, Nikon) equipped with an electronically controlled shutter, filter wheels, and a 14-bit cooled CCD camera (Cool SNAP HQ, Photometrics) controlled by MetaMorph software (Universal Imaging Corp.) by using a 60x/1.4 NA Plan Apo DIC or a 40x/1.4 NA Plan Apo Ph3 objective lens (Nikon). Confocal images were acquired on a spinning disk confocal microscope system, equipped with a CoolSnapHQ camera and 100x/1.4 NA Plan Apo or a 60x/1.4 NA Plan Apo objective lens (Nikon).
A compound that exhibited a SEM of p < 0.05 compared to the DMSO control was declared active.
PubChem Activity Outcome and Score:
The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
List of Reagents:
DLD1 cells (ATCC, CCL-221)
SrcYF (provided by Assay Provider)
DMSO (Sigma 472301)
FITC (Molecular Probes F-1906)
Paraformaldehyde (Sigma P-6148)
Triton (Sigma T8787)
BSA (Sigma A9418)
Alexa-Fluor-568 phalloidin antibody (Molecular Probes, A12380)
Cortactin antibody (Molecular Probes F11)
Alexa-Fluor 568-conjugated anti-mouse secondary antibody (Molecular Probes,A12380)
Mowiol mounting medium (Calbiochem, 475904)
DMEM medium (GIBCO, part 25200)
Hank's Balanced Salt Solution (Invitrogen, part 14025-092)
100X Penicillin-Streptomycin mix (Invitrogen, part 15140)
Trypsin-EDTA solution (Invitrogen, part 25200-056)
Fetal Bovine Serum (Invitrogen, part 16140-071)
DPI (Sigma, D2926)
150 mm tissue culture dishes (Corning, part 430599)
384-well plates (Corning, 3704)
The purpose of this assay is to determine whether a compound that inhibits NOX1 can block invadopodia formation in DLD1 human colon cancer cells. Invadopodia are dynamic phosphotyrosine-rich structures with an actin core and abundant actin regulatory proteins (e.g. cortactin) capable of proteolytically degrading the ECM. They appear as actin protrusions of the ventral plasma membrane and their formation in human cancer cells correlates with their invasiveness both in vitro and in vivo. Recent evidence indicates that NOX-mediated ROS generation is required for invadopodia formation in different cancer cells. In this assay, cells are transfected with tyrosine kinase c-Src, which is required for the formation of functional invadopodia. Cells are then treated with test or control compounds, then stained with invadopodia markers phalloidin or cortactin, and then prepared for confocal and epifluorescence microscopy. As designed, a compound that inhibits NOX1 will inhibit invadopodia formation and result in fewer phalloidin- and contactin-positive structures.
Protocol Summary:
DLD1 cells were transfected with empty vector or with constitutive active Src (SrcYF) to trigger the formation of invadopodia and then treated for 1hr with compound SID 57287864, or DMSO or DPI which were used as negative or positive controls respectively. 24 hrs after transfection, DLD1 cells plated on glass or FITC-labeled gelatin-coated coverslips were fixed in 4% paraformaldehyde (PFA) at room temperature for 10 minutes. Successively, cells were permeabilized in 0.5% Triton for 10 minutes and blocked in 2%BSA in PBS for 45 minutes at room temperature. Cells were then immunolabeled as indicated in the figure legends with appropriate primary and Alexa-Fluor 568-conjugated secondary antibodies. F-actin was detected by using Alexa-Fluor 568-conjugated phalloidin. Cells were mounted on slides with Mowiol mounting medium (Calbiochem) according to the manufacturer's instructions. Epifluorescence images of fixed cells were acquired on an inverted microscope (Eclipse TE 2000-U, Nikon) equipped with an electronically controlled shutter, filter wheels, and a 14-bit cooled CCD camera (Cool SNAP HQ, Photometrics) controlled by MetaMorph software (Universal Imaging Corp.) by using a 60x/1.4 NA Plan Apo DIC or a 40x/1.4 NA Plan Apo Ph3 objective lens (Nikon). Confocal images were acquired on a spinning disk confocal microscope system, equipped with a CoolSnapHQ camera and 100x/1.4 NA Plan Apo or a 60x/1.4 NA Plan Apo objective lens (Nikon).
A compound that exhibited a SEM of p < 0.05 compared to the DMSO control was declared active.
PubChem Activity Outcome and Score:
The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
List of Reagents:
DLD1 cells (ATCC, CCL-221)
SrcYF (provided by Assay Provider)
DMSO (Sigma 472301)
FITC (Molecular Probes F-1906)
Paraformaldehyde (Sigma P-6148)
Triton (Sigma T8787)
BSA (Sigma A9418)
Alexa-Fluor-568 phalloidin antibody (Molecular Probes, A12380)
Cortactin antibody (Molecular Probes F11)
Alexa-Fluor 568-conjugated anti-mouse secondary antibody (Molecular Probes,A12380)
Mowiol mounting medium (Calbiochem, 475904)
DMEM medium (GIBCO, part 25200)
Hank's Balanced Salt Solution (Invitrogen, part 14025-092)
100X Penicillin-Streptomycin mix (Invitrogen, part 15140)
Trypsin-EDTA solution (Invitrogen, part 25200-056)
Fetal Bovine Serum (Invitrogen, part 16140-071)
DPI (Sigma, D2926)
150 mm tissue culture dishes (Corning, part 430599)
384-well plates (Corning, 3704)
Comment
This assay was performed in the laboratory of the Assay Provider with compounds ordered as powders. Details of protocols, compound structures, and results from the original assays can be found in PubChem at the respective AIDs listed below. The results of our probe development efforts can be found at http://mlpcn.florida.scripps.edu/index.php/probes/probe-reports.html.
Result Definitions
| Show more |
| TID | Name | Description | PID§ | Panel Targets | Histogram | Type | Unit | |
|---|---|---|---|---|---|---|---|---|
| Outcome | The BioAssay activity outcome | Outcome | ||||||
| Score | The BioAssay activity ranking score |  | Integer | |||||
| 1 | % Positive Structures [Mock Transfection, Actin Stained] | % of posivive structures in mock-transfected cells | 1 | | Float | % | ||
| 2 | % Positive Structures [Transfected with SrcYF plus DMSO, Actin Stained] | % of positive structures in cells transfected with SrcYF and treated with DMSO | 1 | | Float | % | ||
| 3 | % Positive Structures [Transfected with SrcYF plus DPI (positive control), Actin Stained] | % of positive structures in cells transfected with SrcYF and treated with DPI | 1 | | Float | % | ||
| 4 | % Positive Structures [Transfected with SrcYF plus compound, Actin Stained] | % of positive structures in cells transfected with SrcYF and treated with compound | 1 | | Float | % | ||
| 5 | Qualifier [Actin Stained] | Activity qualifier identifies if the resultant p value was determined to be less than or greater than its listed value. | 1 | String | ||||
| 6 | p value [Actin Stained] | p value compared to DMSO control | 1 | | Float | |||
| 7 | % Positive Structures [Mock Transfection, Contactin Stained] | % of posivive structures in mock-transfected cells | 2 | | Float | % | ||
| 8 | % Positive Structures [Transfected with SrcYF plus DMSO, Contactin Stained] | % of positive structures in cells transfected with SrcYF and treated with DMSO | 2 | | Float | % | ||
| 9 | % Positive Structures [Transfected with SrcYF plus DPI (positive control), Contactin Stained] | % of positive structures in cells transfected with SrcYF and treated with DPI | 2 | | Float | % | ||
| 10 | % Positive Structures [Transfected with SrcYF plus compound, Contactin Stained] | % of positive structures in cells transfected with SrcYF and treated with compound | 2 | | Float | % | ||
| 11 | Qualifier [Contactin Stained] | Activity qualifier identifies if the resultant p value was determined to be less than or greater than its listed value. | 2 | String | ||||
| 12 | p value [Contactin Stained] | p value compared to DMSO control | 2 | | Float |
Additional Information
Grant Number: 1 R03 MH083264-01A1
Classification
PageFrom: